Table 1.
Baseline characteristics.
| Prospective group (n = 7) | Retrospective group (n = 10) | Study population (n = 17) | |
|---|---|---|---|
| Gender | |||
| Males | 3 (43%) | 5 (50%) | 8 (47%) |
| Females | 4 (57%) | 5 (50%) | 9 (53%) |
| Age | |||
| Median (range) | 63 (20–74) | 68 (46–80) | 64 (20–80) |
| ECOG performance status (3 missing data items) | |||
| 0 | 3 (43%) | 2 (29%) | 5 (36%) |
| 1 | 3 (43%) | 5 (71%) | 8 (57%) |
| 2 | 1 (14%) | — | 1 (7%) |
| Stage | |||
| Locally advanced | 1 (14%) | 3 (30%) | 4 (24%) |
| Metastatic | 6 (86%) | 7 (70%) | 13 (76%) |
| Grading (1 missing data item) | |||
| G1 | — | — | — |
| G2 | 3 (43%) | 4 (44%) | 7 (44%) |
| G3 | 4 (57%) | 5 (56%) | 9 (56%) |
| Previous surgery | |||
| Yes | 5 (71%) | 9 (90%) | 14 (82%) |
| Previous chemotherapy | |||
| None | — | 5 (50%) | 5 (29%) |
| Only adjuvant | — | 2 (20%) | 2 (12%) |
| Advanced disease | 7 (100%) | 3 (30%) | 10 (59%) |